Halozyme Therapeutics, Inc. (HALO) Earnings History
Elite Compounder25 years of earnings data (2001–2025) · 5-year EPS CAGR exceeds 18% — top-tier earnings quality
Loading earnings history...
Halozyme Therapeutics, Inc. (HALO) Earnings Overview
As of June 22, 2026, Halozyme Therapeutics, Inc. (HALO) reported trailing twelve-month net income of $349M, reflecting -25.4% year-over-year growth. The company earned $2.84 per diluted share over the past four quarters, with a net profit margin of 22.7%.
Looking at the long-term picture, HALO's 5-year EPS compound annual growth rate (CAGR) stands at +23.0%, indicating exceptional earnings growth. The company achieved its highest annual net income of $444M in fiscal 2024.
Halozyme Therapeutics, Inc. maintains industry-leading profitability with a gross margin of 78.1%, operating margin of 58.4%, and net margin of 22.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including ALNY ($577M net income, 8.4% margin), IONS (-$327M net income, -40.4% margin), ARWR (-$301M net income, -0.2% margin), HALO has outperformed on profitability metrics. Compare HALO vs ALNY →
HALO Earnings vs Peers
Earnings metrics vs comparable public companies
HALO Historical Earnings Data (2001–2025)
25 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $317M | -28.6% | $816M | $2.56 | 22.7% | 58.4% |
| 2024 | $444M | +57.7% | $551M | $3.43 | 43.7% | 54.3% |
| 2023 | $282M | +39.3% | $338M | $2.10 | 34.0% | 40.7% |
| 2022 | $202M | -49.8% | $268M | $1.44 | 30.6% | 40.5% |
| 2021 | $403M | +212.0% | $276M | $2.74 | 90.8% | 62.2% |
| 2020 | $129M | +278.7% | $144M | $0.91 | 48.2% | 53.9% |
| 2019 | -$72M | +10.1% | -$68M | $-0.50 | -36.9% | -34.5% |
| 2018 | -$80M | -227.6% | -$69M | $-0.56 | -52.9% | -45.7% |
| 2017 | $63M | +161.1% | $81M | $0.45 | 19.9% | 25.6% |
| 2016 | -$103M | -219.6% | -$83M | $-0.81 | -70.2% | -56.7% |
| 2015 | -$32M | +52.9% | -$27M | $-0.25 | -23.9% | -20.3% |
| 2014 | -$68M | +18.1% | -$63M | $-0.56 | -90.8% | -83.7% |
| 2013 | -$83M | -55.9% | -$80M | $-0.74 | -152.3% | -146.8% |
| 2012 | -$54M | -170.9% | -$54M | $-0.48 | -126.5% | -126.7% |
| 2011 | -$20M | +62.9% | -$20M | $-0.19 | -35.2% | -35.4% |
| 2010 | -$53M | +8.8% | -$54M | $-0.56 | -390.8% | -398.2% |
| 2009 | -$58M | -19.9% | -$58M | $-0.67 | -426.9% | -427.6% |
| 2008 | -$49M | -103.6% | -$50M | $-0.61 | -555.2% | -575.5% |
| 2007 | -$24M | -62.0% | -$28M | $-0.32 | -628.9% | -740.9% |
| 2006 | -$15M | -11.1% | -$16M | $-0.24 | -1502.6% | -1587.3% |
| 2005 | -$13M | -46.0% | -$14M | $-0.26 | -10435.9% | -10660.7% |
| 2004 | -$9M | -11394.8% | -$9M | $-0.26 | - | - |
| 2003 | $-79,091 | -21.2% | $-79,091 | $-0.01 | -307.7% | -307.7% |
| 2002 | $-65,263 | -64.6% | $-39,387 | $-0.01 | -74.4% | -44.9% |
| 2001 | $-39,652 | - | $-39,706 | $-0.03 | -160.6% | -160.9% |
Download Data
Export HALO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HALO — Frequently Asked Questions
Quick answers to the most common questions about buying HALO stock.
What is HALO earnings per share (EPS)?
HALO trailing twelve-month (TTM) diluted EPS is $2.84, reflecting -25.4% year-over-year growth. The 5-year EPS CAGR is +23.0%. Complete EPS history from 2001 to 2025 is available in the table on this page.
What is Halozyme Therapeutics, Inc.'s net income?
Halozyme Therapeutics, Inc. (HALO) trailing twelve-month net income is $349M as of 2025. Earnings declined -25.4% year-over-year. Halozyme Therapeutics, Inc. has been profitable for 6 consecutive years.
Is HALO profitable?
Yes, HALO is profitable with a TTM net income of $349M and a net profit margin of +22.7%. Halozyme Therapeutics, Inc. has generated profits for 6 consecutive years.
What is HALO's earnings growth rate?
HALO compound annual EPS growth rates (CAGR): 1-Year: -25.4%, 3-Year: +21.1%, 5-Year: +23.0%, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2001 to 2025.
What are HALO's profit margins?
Halozyme Therapeutics, Inc. net profit margin is +22.7%, operating margin is +58.4%, and gross margin is +78.1%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +153.6%.
Is HALO growing earnings?
HALO earnings are declining — EPS fell -25.4% year-over-year. TTM net income dropped to $349M. This contrasts with the 5-year CAGR of +23.0%.
What was HALO's best earnings year?
Halozyme Therapeutics, Inc.'s highest annual net income on record is $444M, achieved in fiscal year 2024. Earnings history on this page spans 2001 to 2025 and includes all annual and quarterly figures.
What were HALO's earnings last quarter?
HALO's most recent reported quarter was Q1 2026. Net income was $150M with diluted EPS of $1.22. For a full breakdown of all quarters, see the quarterly earnings table on this page.